*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Dr. Quyyumi will be discussing his Amorcyte Myocardial Repair study, a Phase I clinical trial in which CD34+ bone-marrow-derived autologous cells are injected into the heart to treat acute myocardial infarctions. Heart attacks, which affect more than 1 million Americans a year, can cause congenital heart failure, where the heart muscle is damaged and can no longer effectively pump blood to the rest of the body. Endothelial protenitor cells, or EPCs, are cells that have been shown to aid in new blood vessel formation after injury. This study looks into the effect of treating damaged heart tissue with EPCs, with the hopes that these cells facilitate development of new blood vessels that may aid in repair of the heart muscle.
